AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, ...

AtriCure today announced the first use of its newest AtriClip device for minimally invasive concomitant procedures.

Building upon the proven technology of AtriCure’s AtriClip platform as the most widely implanted surgical LAA device globally, the AtriClip PRO-Mini device is preloaded with the smallest ...

It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices ...

Building upon the proven technology of AtriCure’s AtriClip platform as the most widely implanted surgical LAA device globally, the AtriClip PRO-Mini device is preloaded with the smallest surgical LAA ...

No significant difference was observed in clinical event rates in relation to the device implanted. "The Watchman's single-lobe design may create conditions more conducive to thrombus formation by not ...

A study published in Brain Communications highlights a new approach to treating drug-resistant epilepsy. Researchers at Mayo ...

Michael Carrel, President and CEO of AtriCure, emphasized the company’s dedication to creating the most effective surgical LAA devices available. He stated that the AtriClip PRO-Mini device is a ...

WPI Researcher Jiawei Yang pairs hydrogels with glue-like polymers to build a new class of bioadhesive implants that will ...

Chuck Moon, a congestive heart failure patient, experienced significant improvement in his quality of life after receiving a Barostim device implant. The Barostim device is a new technology that ...